The NEJM reports that systemic lupus erythematosus (SLE) patients treated with iberdomide, a cereblon modulator, was effective at yielding a significant SRI-4 clinical response after 24 weeks.  Iberdomide works by promoting degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development and autoimmunity.

Rheumatoid arthritis associated bronchiectasis (RA-BR) is uncommon, and is unrelated to interstitial lung disease (ILD), but like ILD, can substantially impact RA outcomes. A case-control study from the Mass General Brigham Biobank compared RA-BR (57 cases) and RA controls without RA-related lung disease (n-360) by clinical parameters and CT chest imaging results. 

Analysis of emergency department visits from two UK hospitals shows a high rate of hospitalization, and low use of urate-lowering therapies (ULT) and treat-to-target (T2T) management.  Between 2017 and 2020 there were 1,220 emergency attendances for gout flares -  23.5% required hospitalization (median length of stay: 3.6 days). Moreover, 10% of patients had recurrent ER visits attendances for gout flares. 

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD). Previously environmental pollutants have been linked to an increased risk of RA onset and also, flares of RA or lupus.